Clinic
Memorial Hospital of Polk County
Memorial Hospital of Polk County was paid $10.49M by Medicaid between Jan 2020 and Nov 2024, across 57 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL OF POLK COUNTY
LIVINGSTON, TX 77351
LIVINGSTON, TX 77351
33aNPI1689650616assigned 12/21/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$10.49M
24GClaims88,958
24DCodes billed57
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#43 of 320
Median peer was paid$205K
This provider vs. median51×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,310 | $226K | |
| 2021 | 24,677 | $2.07M | |
| 2022 | 30,324 | $3.73M | |
| 2023 | 23,660 | $3.53M | |
| 2024incomplete | 6,987 | $933K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 7,193 | 6,701 | $3.51M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 11,273 | 10,777 | $3.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 4,508 | 4,144 | $2.46M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 2,969 | 2,671 | $267K |
| 71045 | Radiologic examination, chest; single view | 2.3% | 3,574 | 3,290 | $237K |
| 80053 | Comprehensive metabolic panel | <1% | 8,363 | 7,505 | $80K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 235 | 223 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,319 | 8,213 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 289 | 278 | $57K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,707 | 2,450 | $55K |
| 59025 | Fetal non-stress test | <1% | 480 | 329 | $54K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 252 | 223 | $51K |
45 more codes
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 263 | $48K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,645 | $48K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 496 | $46K |
| 87430 | <1% | 2,079 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 856 | $28K |
| 81001 | <1% | 6,757 | $22K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,002 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 298 | $16K |
| 87070 | <1% | 1,493 | $16K | |
| 81025 | <1% | 1,202 | $11K | |
| 84484 | <1% | 1,671 | $10K | |
| 83690 | <1% | 1,559 | $9K | |
| 83880 | <1% | 623 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 200 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,006 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $3K |
| 87420 | <1% | 207 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 197 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,891 | $3K |
| 87428 | <1% | 102 | $2K | |
| CP007 | <1% | 67 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 701 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 107 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 28 | $886.42 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $814.57 |
| 87040 | <1% | 162 | $740.84 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 98 | $699.52 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 199 | $695.50 |
| 87077 | <1% | 464 | $688.44 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 508 | $676.21 |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,582 | $337.54 |
| 83605 | <1% | 125 | $324.86 | |
| 85610 | <1% | 207 | $252.42 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16 | $247.43 |
| 85730 | <1% | 116 | $212.16 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 40 | $172.68 |
| 83735 | <1% | 45 | $150.38 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $146.01 |
| 82550 | <1% | 65 | $125.83 | |
| 87186 | <1% | 94 | $74.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 17 | $49.25 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 280 | $17.00 |
| 82042 | <1% | 16 | $6.54 | |
| A9270 | Non-covered item or service | 0% | 248 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGLASS, MEGAN (REIMBURSEMENT ANALYST)
| Provider | Location | Paid |
|---|---|---|
| Memorial Health System of East Texas | Lufkin, TX | $8.62M |
| Memorial Medical Center San Augustine | San Augustine, TX | $694K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.